CD138是在大多数人的血浆和多发性骨髓瘤细胞中发现的一种蛋白多糖。一期临床试验中5例患者使用CD138-CAR-T,其中4例患者病情稳定,1例患者病情仍有进展。另一名患者接受了另一种CD138-CAR-T的浸润性浆细胞白血病治疗,并且获得部分响应,但随后在输液3...
Background: Despite recurrent and activating mutations, including MYD88, CXCR4, ARID1A, KMT2D, and CD79B were identified, the genetic basis for Waldenstrm's Macroglobulinemia (WM) and the risk of progression of IgM MGUS to WM remain to be fully elucidated. Methods: We investi...
领导团队与企业合作联合在国内率先采用新型第二代CD19-41BB-CART CAR-T细胞治疗难治复发的急性B淋巴细胞白血病;此后联合开发了多种靶点的CART临床用于治疗血液肿瘤,包括CD1a、CD4、CD7、CD20、CD22、CD30、CD33、CD70、CD79b、CD...
本发明公开了靶向CD138和CD19的免疫细胞组合及其应用.具体地,本发明公开了靶向CD138的CART细胞和靶向CD19的CART细胞的免疫细胞组合,所述的免疫细胞组合可以用于制备预防和/或治疗肿瘤的药物或制剂.本发明还提供了包含所述免疫细胞组合的药物组合物和制剂.
Plasma cell leukemia (PCL) is an uncommon and aggressive disease caused by the clonal proliferation of atypical plasma cells with phenotypical abnormalities similar to those seen in multiple myeloma (MM), although at different rates. Here, we report a case of IgD PCL with a very unusual CD138...
符合条件为患者有r/r MM,CD138-IHC检测骨髓中血浆细胞≥10%,以IMWG标准检测疾病。流式细胞术检测CD138+浆细胞BCMA。通过阳性选择分离CD8+和CD4+T细胞。在不同的培养基中刺激T细胞,并用慢病毒载体(BCMA scFv)结合41BB和CD3 zeta信号转导。 扩增后,细胞产物以1:1的比例配制成CD4+:CD8+BCMA CAR-T细胞。为了...
(-)CD138(+), revealed that they were Pax5 (a B-cell-specific transactivator)-negative. These results suggest that CD19(-)CD45(low/-) fully differentiated plasma cells enrich for long-lived and tumor-initiating cells whereas B cells or plasmablasts do not. Leukemia (2012) 26, 2530-2537;...
病理免疫组化:弥漫性大B细胞淋巴瘤,非特指型,非生发中心起源(Hans模型),双重表达淋巴瘤;Bcl-2(80%+),Bcl-6(+),CD3(-),CD5(-),CD10(-),CD15(-),CD30(-),CD79a(NS),CD138(-),C-myc(热点40%+),Ki-67(80%+),MUM1(+),PAX5(+)。CD20(+,95%强),CD19(+,95%强),CD22(+,95%强),CD...
MACSprep Multiple Myeloma CD138 MicroBeads, human/人MACSprep多发性骨髓瘤CD138磁珠 产品类型:B细胞分选 规格:用于 40 mL 全血 130-111-744 我要询价 添加 Miltenyi MACSprep Chimerism CD19 MicroBeads, human/人MACSprep嵌合体CD19磁珠 产品类型:B细胞分选 ...
2022年7月14日/医麦客新闻 eMedClub News/--近日,瓴路药业和ADC Therapeutics SA创建的合资企业瓴路爱迪思宣布,针对旗下全球首个且唯一一个靶向CD19的抗体偶联药物(ADC)ZYNLONTA与利妥昔单抗联合疗法的在LOTIS-5确证性三期全球临床试验在中国完成了首例患者给药。此项临床试验将通过对比标准免疫化学疗法,评估ZYNLONTA...